Effect of Aspirin on Brain Metastasis of Lung Cancer and Its Possible Mechanism

TANG Ming-ke, SUN Yue-ming, QIN Li-juan. et al

Abstract

To determine the effect of prostaglandin E2 (PGE2) on brain metastasis of lung cancer, and to explore the possible mechanism of aspirin (PGE2 inhibitor) reducing brain metastasis of lung cancer. MethodsRadioimmunoassay was performed to measure the expression level of PGE2 in cell supernatant collected from cells treated with or without aspirin (8 mmol/L) at different time points. After establishing in vitro blood-brain barrier (BBB) model using Transwell, lung cancer cells was added to upper chamber of transwell and was then treated with aspirin (8 mmol/L). Western blot was used to examine the expression of occludin protein in brain microvascular endothelial cells. The permeability changes of BBB model in vitro were determined using horseradish peroxides. The number of lung cancer cells passing through BBB model in vitro was counted with Hemocytometer. Effect of aspirin on brain metastasis of lung cancer was observed in nude mice in the animal level. ResultsPGE2 level decreased and reached minimum level 120 min after aspirin treatment in lung cancer cells culture fluid. Occludin expression increased and reached maximum level 120 min after aspirin treatment in brain microvascular endothelial cells. At the same time, permeability of BBB and number of lung cancer cells passing through BBB also reached the lowest value 120 min after aspirin treatment. Aspirin significantly reduced the incidence of brain metastasis of lung cancer in animal model. ConclusionAspirin reduced occurrences of the brain metastasis of lung cancer in animal model, which may be caused by inhibition of PGE2 released by lung cancer cells and upregulation of occludin expression therefore leading to decrease in BBB permeability.

 

Keywords: Lung cancer, Brain metastasis of lung cancer, Aspirin, Prostaglandin, Blood-brain barrier, Occludin protein

 

Full Text:

PDF


References


SATOH H, ISHIKAWA H. YAMASHITA YT, et al. Patterns of brain metatasis in lung cancer. Oncol Rep,2001 ,8 (4):781-783.

BINDER D. TEMMESFELD-WOLLBRUCK B. WURM R, et al. Brain metastases of lung cancer. Dtsch Med Wochenschr,2006,131(4): 165-171.

ZIMMERMANN S, DZIADZIUSZKO R, PETERS S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev, 2014,40(6); 716-722.

LEE HW, LEE JI, LEE SJ, et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res,2015 ,21 (5): 1172-1182.

JONSSON F, YIN L, LUNDHOLM C, et al. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer,2013,109(7); 1921-1925.

ZHONG X, FAN Y, RITZENTHALER JD, et al. Novel link between prostaglandin E2 ( PGE2 ) and cholinergic signaling in lung cancer: the role of c-Jun in PGE2-induced al nicotinic acetylcholine receptor expression and tumor cell proliferation. Thorac Cancer,2015,6(4);488-500.

HARFORD-WRIGHT E, LEWIS KM, VINK R. Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface. Recent Pat CNS Drug Discov,2011,6( 1);31-40.

THOMPSON EM. FRENKEL EP, NEUWELT EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology,2011,76(1):87-93.

LEMASSON B, SERDUC R, MAISIN C, et al. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology, 2010, 257 (2):342-352.

PANG Z. FENG L, HUA R, el al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm, 2010,7(6):1995-2005.

BLACK KL, YIN D. ONG JM. et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res,2008,1230;290-302[2016- 10-10]. http://www. sciencedirect. com/science/article/pii/ S0006899308016028. doi: 10. 1016/j. brainres. 2008. 06. 122.

CHO MS, VASQUEZ HG, RUPAIMOOLE R, et al. Autocrine effects of tumor-derived complement. Cell Rep, 2014,6(6):1085-1095.

ZIMMERMANN S, DZIADZIUSZKO R. PETERS S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev,2014,40(6):716-722.

BA ENA CP. D’ AM ICO RC, SLONGO H. et al. The effectiveness of aspirin for migraine prophylaxis; a systematic review. Sao Paulo Med J.2017,135(1) ;42-49.

ZHU HM, WU T, CUI L. Study of aspirin on proliferation and apoptosis of human lung Adenocarcinoma cell lines SPCA-1 in vivo. Chinese Pharmacological Bulletin. 2004 , 20 (6):640-643.

FUKUMOTO K. TAKAGI N, YAMAMOTO R. et al. Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur J Pharmacol, 2010,640(1/2/3) ;82-86.

HARTLERODE AJ, MORGAN MJ, WU Y, et al. Recruitment and activation of the ATM kinase in the absence of DNA damage sensors. Nat Struct Mol Biol, 2015,22(9): 736-743.

FU T, WANG L. JIN X, et al. Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro. Acta Pharm Sin.2016.37(4):505-518.

BOMMER UA, IADEVAIA V, CHEN J. et al. Growth- factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the Pl3-K/Akt/ mTORCl signalling pathway. Cell Signal.2015.27(8): 1557- 1563.

CHU X, CHEN L, WANG J, et al. SiRNA-mediated surviving inhibition enhances chemo-or radiosensivity of colorectal cancer cells in tumor-bearing nude mice. Hepatogastroenterology,2012, 57(104 ); 1445-1452.


Refbacks

  • There are currently no refbacks.